23andMe and GSK Announce Collaboration to Use Genetic Data to Research Diseases

As part of the deal GSK is investing $300 million in 23andMe. Vice President of Business Development at 23andMe, Emily Drabant Conley, explains how the partnership will play out over the next four years.
close
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.